Klin Farmakol Farm. 2019;33(2):36-43 | DOI: 10.36290/far.2019.034

Drug-drug interactions of frequently prescribed antidepressants

Michal Prokeš, Josef Suchopár
DrugAgency, a.s., Praha

This article describes drug-drug interactions of antidepressants. Potentially fatal pharmacodynamic interactions include serotonin syndrome, whose diagnosis is difficult. QT prolongation is a marker of increased risk of ventricular tachycardia. Administration of SSRIs and NSAs increases the risk of bleeding, especially from GIT. From pharmacodynamic interactions, the article highligts interactions via CYP2D6. Many antidepressants and antipsychotics are CYP2D6 substrates, with paroxetine, fluoxetine and fluvoxamine being CYP2D6 inhibitors. Some of the interactions are contraindicated, in other cases doctor should consider pros and cons, and patients should be carefully monitored.

Keywords: antidepressants, CYP2D6, serotonin syndrome, QT interval prolongation

Received: September 23, 2019; Accepted: September 24, 2019; Prepublished online: September 24, 2019; Published: July 10, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Prokeš M, Suchopár J. Drug-drug interactions of frequently prescribed antidepressants. Klin Farmakol Farm. 2019;33(2):36-43. doi: 10.36290/far.2019.034.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Suchopár J, Prokeš M, Suchopár O. Spotřeba antidepresiv v České republice ve srovnání s ostatními vyspělými zeměmi. Remedia 2016; 26(6): 560-566.
    2. Raboch J, Červený R. Deprese, novelizace 2018. Centrum doporučených postupů pro praktické lékaře, dostupné z: www.svl.cz
    3. Slanař O, Drazd'áková M, Babiárová K, Pechandová K, Buzková H, Perlík F, Zima T. Genotyping of CYP2D6 and CYP2C19. Cas Lek Cesk 2007; 146: 708-711. Go to PubMed...
    4. Ústav lékařské biochemie a laboratorní diagnostiky VFN, dostupné z: https://ulbld.lf1.cuni.cz/seznam-lab-vysetreni?vysetreni=1374
    5. SÚKL: Farmakoterapeutické informace 2015, 1: dostupné z: http://www.sukl.cz/sukl/2015
    6. Prokeš M, Suchopár J. Serotoninový syndrom: co bychom o něm měli vědět. Med. praxi 2014; 11(5): 226-230.
    7. Beakley BD, Kaye AM, Kaye AD. Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review. Pain Physician 2015; 18: 395-400. Go to original source... Go to PubMed...
    8. Maniscalco I, Toffol E, Giupponi G, Conca A. The interaction of Rhodiola rosea and antidepressants. A case report. Neuropsychiatr 2015; 29: 36-38. Go to original source... Go to PubMed...
    9. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: A retrospective survey. Clin Infect Dis 2006; 43: 180-187. Go to original source...
    10. Attar-Herzberg D, Apel A, Gang N, et al. The serotonin syndrome: Initial misdiagnosis. Isr Med Assoc J 2009; 11: 367-370. Go to PubMed...
    11. Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. Q J Med 2003; 96: 635-642. Go to original source...
    12. Prokeš M, Suchopár J. Prodloužení intervalu QT způsobené léky. Med. praxi 2014; 11(1): 34-39.
    13. Digby G, MacHaalany J, Malik P, et al. Multifactorial QT interval prolongation. Cardiology Journal 2010; 17: 184-188. Go to PubMed...
    14. Woosley RL, Heise CW, Romero KA (www.CredibleMeds.org), QTdrugs List, [1. 3. 2018], AZCERT, Inc., 1822 Innovation Park Dr., Oro Valley, AZ 85755, USA, https://www.crediblemeds.org/
    15. Helin-Salmivaara A, Huttunen T, Grönroos JM, et al. Risk of serious upper gastrointestinal events with concurrent use of NSADs and SSRI: a case-control study in the general population. Eur J Clin Pharmacol 2007; 63: 403-408. Go to original source...
    16. de Abajo FJ, Garcia-Rodriques LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxin therapy. Arch Gen Psychiatry 2008; 65; 65(7): 795-803. Go to original source... Go to PubMed...
    17. Gray SL, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern med 2015; 175(3): 401-407. Go to original source...
    18. Topinková E. Nežádoucí účinky antimuskarinik na centrální nervový systém. Urol List 2012; 10: 69-74.
    19. Sheikh-Taha M, Dimassi H. Potentially inappropriate home medications among older patients with cardiovascular disease admitted to a cardiology service in USA. BMC Cardiovascular Disorders 2017; 17: 198. Go to original source... Go to PubMed...
    20. Lu X, Wang X. Hyponatremia induced by antiepileptic drugs in patients with epilepsy. Expert Opin Drug Saf 2017; 16(1): 77-87. Go to original source...
    21. Wang D, Lai J, Lu S, Huang M, et al. Rapid-onset hyponatremia and delirium following duloxetine treatment for postherpetic neuralgia: Case report and literature review. Medicine (Baltimore). 2018 Nov; 97(46): e13178. Go to original source... Go to PubMed...
    22. Yoon HJ, Lee KY, Sun IO. Clinical severity of drug-induced hyponatremia: thiazides vs. psychotropics. Clin Nephrol. 2016 Jun; 85(6): 321-325. Go to original source... Go to PubMed...
    23. Databáze lékových interakcí DrugAgency, 2019, Elektronická publikace. Dostupné z: http://lekoveinterakce.cz
    24. Raboch J, Uhlíková P, Hellerová P, et al. Psychiatrie: Doporučené postupy psychiatrické péče IV. 2014. [cit. 2019-01-16]. Dostupné z: https://psychiatrie.cz/images/stories/deni_v_oboru/doporucene-postupy-4-2014.pdf
    25. Karki SD, Masood GR. Combination risperidone and SSRI-induced serotonin syndrome. Ann Pharmacother 2003; 37(3): 388-391. Go to original source... Go to PubMed...
    26. Saito M,Yasui-Furukori N, Nakagami T, et al. Dose-depentent interaction of paroxetine with risperidone in schizophrenic patients. J Clin Pharmacol 2005; 25(6): 527-532. Go to original source...
    27. Stout SM, Nielsen J, Welage LS, et al. The influence of metoprolol dosage release formulation on the pharmacokinetic drug interactions with paroxetine. J Clin Pharmacol 2011; 51: 389-396. Go to original source... Go to PubMed...
    28. Laugesen S, Enggaard TP, Pedersen RS, et al. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the setereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 2005; 77(4): 312-323. Go to original source...
    29. Lantz MS, Buchalter EN, Giambanco V. Serotonin syndrome following the administration of tramadol with paroxetine. Int J Geriatr Psychiatry 1998; 13: 343-345. Go to original source...
    30. de Jong J, Hoogenboom B, van Troostwijk LD, de Haan L. Interaction of olanzapine with fluvoxamine. Psychopharmacology 2001; 155(2): 219-220. Go to original source...
    31. Weigmann H, Gerek S, Zeisig A, et al. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 2001 Aug; 23(4): 410-413. Go to original source... Go to PubMed...
    32. Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Saf 1991; 6(6): 460-462. Go to original source...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.